Healthcare

Published coverage says new orders improved during the quarter but finished below the company's signed-order targets, and orders lead sales. GLP-1 customers made up about 17% to 18% of third-quarter revenue. Management said weaker GLP-1 revenue was offset by other biologic drugs, which grew …

The oral Wegovy launch is the visible engine. Quarterly sales reached DKK 5,394 million, and the company says it took more than 50% of branded obesity new patient starts in the US for Wegovy overall. An Ozempic pill launched in the US in May, …

Organigram (NASDAQ:OGI) plans a privatePlacementwith BAT of 141.0 million shares, described as 100 million pounds or about CAD 187.5 million, alongside an ATBCreditFacilityof up to CAD 210 million. The per-share price for the placement is inconsistent across the release, so it is left out …

The RRP-001 trial enrolled 32 adults, and all of them completed it. In the 26-patient efficacy group, which had a median of 4.5 surgeries in the prior year, no further excisions were needed during dosing, and 7 patients, or 27%, reached a complete response …

Key HighlightsIDEXX Laboratories (NASDAQ:IDXX) gained about 22% on November 2, 2026, closing near USD 671.64 afterRevenuerose 10% to about USD 1.214 billion and 2026Earningsguidance was raised.Neurocrine Biosciences (NASDAQ:NBIX) rose 13.42% on November 3 after third-quarter revenue climbed 41% to USD 1,123 million and Ingrezza …

Key HighlightsNovo Nordisk (NYSE:NVO) reported third-quarter net sales of DKK 79,195 million, up 4% at constant exchange rates, with Wegovy pill sales of DKK 5,394 million, and its shares rose about 5% to 6% early on November 4, 2026.Pfizer (NYSE:PFE) raised 2026Revenueguidance to USD …

Key HighlightsIDEXX Laboratories (NASDAQ:IDXX) gained about 22% on November 2, 2026, closing near USD 671.64 afterRevenuerose 10% to about USD 1.214 billion and dilutedEarningsof USD 4.01 a share beat estimates.Revvity (NYSE:RVTY) closed up 7.84% on November 3 after revenue of USD 728.9 million and …